NKTR
Nektar Therapeutics
40.80$
+1.3%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -174.5% | -197.0% | -221.3% | -160.5% | -182.1% | -158.3% | -469.0% | -409.3% | -413.6% | -297.9% | -407.9% | -747.9% | -428.3% | |
| 7.0% | 6.9% | 7.4% | 6.2% | 4.1% | 1.1% | 4.1% | -5.9% | 1.7% | -1.7% | 1.4% | 1.5% | 0.2% | |
| 33.8% | 30.4% | 27.7% | 23.1% | 22.3% | 16.5% | 37.3% | 31.2% | 26.1% | 10.1% | 30.9% | 33.2% | 22.0% | |
| -13.4% | -19.8% | -30.6% | 46.0% | 4.4% | -39.5% | -1.4% | -32.0% | -86.2% | -106.0% | -0.6% | -460.1% | -146.5% | |
| 0.1% | 1.0% | 0.7% | 0.8% | 2.8% | 1.6% | 0.0% | 0.3% | 1.0% | 0.1% | 0.2% | 1.1% | 0.5% | |
| 233.6% | 72.8% | 89.0% | 72.3% | 191.2% | 206.4% | 417.7% | 444.0% | -804.7% | 1.7% | -3,229.8% | -3,939.5% | -1,546.8% | |
| 0.0% | – | -13.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | |
| -268.9% | 0.1% | 194.1% | 0.1% | 0.1% | 0.3% | 0.1% | 1.9% | 1,201.7% | 177.3% | 4,875.7% | 3,598.5% | 1,968.3% | |
| 58.8% | -123.8% | 67.4% | -88.7% | 8.9% | 48.5% | -51.2% | 36.6% | -16.6% | -5.5% | 1,184.7% | -1,088.8% | 27.9% | |
| -174.6% | -198.0% | -222.0% | -161.3% | -184.9% | -159.9% | -469.0% | -409.6% | -414.5% | -298.0% | -408.0% | -749.0% | -428.7% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.